These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 9819001)

  • 21. Differential in vitro effects of the platelet glycoprotein IIb/IIIa inhibitors abixicimab or SR121566A on platelet aggregation, fibrinogen binding and platelet secretory parameters.
    Klinkhardt U; Kirchmaier CM; Westrup D; Breddin HK; Mahnel R; Graff J; Hild M; Harder S
    Thromb Res; 2000 Feb; 97(4):201-7. PubMed ID: 10674406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycoprotein IIb/IIIa inhibitors increase COAT-platelet production in vitro.
    Hamilton SF; Miller MW; Thompson CA; Dale GL
    J Lab Clin Med; 2004 May; 143(5):320-6. PubMed ID: 15122176
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New orally active non-peptide fibrinogen receptor (GpIIb-IIIa) antagonists: identification of ethyl 3-[N-[4-[4-[amino[(ethoxycarbonyl) imino]methyl]phenyl]-1,3-thiazol-2-yl]-N-[1-[(ethoxycarbonyl)methyl]pip erid -4-yl]amino]propionate (SR 121787) as a potent and long-acting antithrombotic agent.
    Badorc A; Bordes MF; de Cointet P; Savi P; Bernat A; Lalé A; Petitou M; Maffrand JP; Herbert JM
    J Med Chem; 1997 Oct; 40(21):3393-401. PubMed ID: 9341914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel nonpeptide antiplatelet glycoprotein IIb/IIIa receptor antagonist, DMP754: receptor binding affinity and specificity.
    Mousa SA; Forsythe M; Lorelli W; Bozarth J; Xue CB; Wityak J; Sielecki TM; Olson RE; DeGrado W; Kapil R; Hussain M; Wexler R; Thoolen MJ; Reilly TM
    Coron Artery Dis; 1996 Oct; 7(10):767-74. PubMed ID: 8970768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in the ability of glycoprotein IIb-IIIa antagonists to exert and maintain their inhibitory effects on the binding of fibrinogen.
    Schneider DJ; Baumann PQ; Whitaker DA; Sobel BE
    J Cardiovasc Pharmacol; 2005 Jul; 46(1):41-5. PubMed ID: 15965353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyamines inhibit both platelet aggregation and glycoprotein IIb/IIIa activation.
    Corona-de-la-Peña N; Uribe-Carvajal S; Barrientos-Rios R; Matias-Aguilar L; Montiel-Manzano G; Majluf-Cruz A
    J Cardiovasc Pharmacol; 2005 Aug; 46(2):216-21. PubMed ID: 16044034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet activation during treatment with a glycoprotein IIb/IIIa antagonist.
    Seiffert D; Thomas BE; Bradley JD; Munzer DA; Tchinnes MA; Kornhauser DM; Cain VA; Hua TA; Feuerstein GZ; Martin DE; Stern AM
    Platelets; 2003 May; 14(3):179-87. PubMed ID: 12850842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.
    Dickfeld T; Ruf A; Pogatsa-Murray G; Müller I; Engelmann B; Taubitz W; Fischer J; Meier O; Gawaz M
    Thromb Res; 2001 Jan; 101(2):53-64. PubMed ID: 11342206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ; Taatjes DJ; Sobel BE
    Cardiovasc Res; 2000 Jan; 45(2):437-46. PubMed ID: 10728364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation.
    Rozalski M; Boncler M; Golanski J; Watala C
    Biochem Pharmacol; 2001 Nov; 62(10):1399-408. PubMed ID: 11709200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of activated platelets and platelet-leukocyte aggregates in horses.
    Weiss DJ; Evanson OA
    Am J Vet Res; 1997 Aug; 58(8):823-7. PubMed ID: 9256963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.
    Hoffmann P; Bernat A; Savi P; Herbert JM
    J Cardiovasc Pharmacol; 1997 Sep; 30(3):360-6. PubMed ID: 9300321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin.
    Mousa SA; Forsythe M; Bozarth J; Jin F; Confalone PN
    Coron Artery Dis; 2000 Oct; 11(7):563-70. PubMed ID: 11023245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelet activity of green tea catechins is mediated by inhibition of cytoplasmic calcium increase.
    Kang WS; Chung KH; Chung JH; Lee JY; Park JB; Zhang YH; Yoo HS; Yun YP
    J Cardiovasc Pharmacol; 2001 Dec; 38(6):875-84. PubMed ID: 11707691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The GP IIb/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation.
    Straub A; Wendel HP; Azevedo R; Ziemer G
    Eur J Cardiothorac Surg; 2005 Apr; 27(4):617-21. PubMed ID: 15784360
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active GPIIb-IIIa conformations that link ligand interaction with cytoskeletal reorganization.
    Mondoro TH; White MM; Jennings LK
    Blood; 2000 Oct; 96(7):2487-95. PubMed ID: 11001901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The fibrinogen gamma chain dodecapeptide inhibits agonist-induced aggregation of rabbit platelets and fibrinogen binding to rabbit glycoprotein IIb-IIIa.
    Rand ML; Packham MA; Taylor DM; Yeo EL; Gemmell CH; Patil S; Lam SC
    Thromb Haemost; 1999 Dec; 82(6):1680-6. PubMed ID: 10613655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
    Ito H; Miyakoda G; Mori T
    Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.